Time multiplexed nuclear imaging using targeted nanoparticles for accurate tumors margin detection

2021 ◽  
Author(s):  
Ariel Schwarz ◽  
Yossef Danan ◽  
Rachel Bar-Shalom ◽  
Amir Shemer
Keyword(s):  
Nuclear Imaging ◽  
Targeted Nanoparticles ◽  
Margin Detection

174 Myocardial perfusion by intravenous echo contrast and by nuclear imaging

1999 ◽  
Vol 1 ◽  
pp. S31-S31
Author(s):  
M MORALES ◽  
D ROVAI ◽  
A GIMELLI ◽  
C MARINI ◽  
U STARTARI ◽  
...  
Keyword(s):  
Myocardial Perfusion ◽  
Nuclear Imaging

Accessing Targeted Nanoparticles to the Brain: The Vascular Route

2014 ◽  
Vol 21 (36) ◽  
pp. 4092-4099 ◽  
Author(s):  
A. Burkhart ◽  
M. Azizi ◽  
M.S. Thomsen ◽  
L.B. Thomsen ◽  
T. Moos
Keyword(s):  
Targeted Nanoparticles ◽  
The Brain

Theranostic Potential of Targeted Nanoparticles for Brain Cancer

2017 ◽  
Vol 17 (18) ◽  
Author(s):  
Ajita Bhatt ◽  
Ekta Gurnany ◽  
Anuj Modi ◽  
Arvind Gulbake ◽  
Aviral Jain
Keyword(s):  
Brain Cancer ◽  
Targeted Nanoparticles

Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity

2020 ◽  
Vol 20 (16) ◽  
pp. 1966-1980
Author(s):  
Jaleh Varshosaz ◽  
Saeedeh Fardshouraki ◽  
Mina Mirian ◽  
Leila Safaeian ◽  
Setareh Jandaghian ◽  
...  
Keyword(s):  
Controlled Release ◽  
Side Effects ◽  
Kinase Inhibitor ◽  
Lymphoblastic Leukemia ◽  
Drug Carrier ◽  
Free Drug ◽  
Jurkat Cells ◽  
Targeted Nanoparticles ◽  
Inhibitor Drug ◽  
Histopathological Results

Background: Using imatinib, a tyrosine kinase inhibitor drug used in lymphoblastic leukemia, has always had limitations due to its cardiotoxicity and hepatotoxicity side effects. The objective of this study is to develop a target-oriented drug carrier to minimize these adverse effects by the controlled release of the drug. Methods: KIT-5 nanoparticles were functionalized with 3-aminopropyltriethoxysilane and conjugated to rituximab as the targeting agent for the CD20 positive receptors of the B-cells. Then they were loaded with imatinib and their physical properties were characterized. The cell cytotoxicity of the nanoparticles was studied by MTT assay in Ramos (CD20 positive) and Jurkat cell lines (CD20 negative) and their cellular uptake was shown by fluorescence microscope. Wistar rats received an intraperitoneal injection of 50 mg/kg of the free drug or targeted nanoparticles for 21 days. Then the level of aspartate Aminotransferase (AST), alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Lactate Dehydrogenase (LDH) were measured in serum of animals. The cardiotoxicity and hepatotoxicity of the drug were also studied by hematoxylin and eosin staining of the tissues. Results: The targeted nanoparticles of imatinib showed to be more cytotoxic to Ramos cells rather than Jurkat cells. The results of the biochemical analysis displayed a significant reduction in AST, ALT, ALP, and LDH levels in animals treated with targeted nanoparticles, compared to the free drug group. By comparison with the free imatinib, histopathological results represented less cardiotoxicity and hepatotoxicity in the animals, which received the drug through the current designed delivery system. Conclusion: The obtained results confirmed that the rituximab targeted KIT-5 nanoparticles are promising in the controlled release of imatinib and could decrease its cardiotoxicity and hepatotoxicity side effects.

Nuclear Imaging

2020 ◽  
pp. 37-45
Author(s):  
William Brawner
Keyword(s):  
Nuclear Imaging

scholarly journals Imaging Evaluation of Pulmonary and Non-Ischaemic Cardiovascular Manifestations of COVID-19

Diagnostics ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 1271
Author(s):  
Sebastiano Cicco ◽  
Antonio Vacca ◽  
Christel Cariddi ◽  
Rossella Carella ◽  
Gianluca Altamura ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Myocardial Injury ◽  
Nuclear Imaging ◽  
Emergency Setting ◽  
Imaging Evaluation ◽  
Coagulation Abnormalities ◽  
Cardiovascular Involvement ◽  
Highly Sensitive ◽  
Inflammatory Syndrome ◽  
Inflammatory Burden

Coronavirus Disease 2019 (COVID-19) has been a pandemic challenge for the last year. Cardiovascular disease is the most described comorbidity in COVID-19 patients, and it is related to the disease severity and progression. COVID-19 induces direct damage on cardiovascular system, leading to arrhythmias and myocarditis, and indirect damage due to endothelial dysfunction and systemic inflammation with a high inflammatory burden. Indirect damage leads to myocarditis, coagulation abnormalities and venous thromboembolism, Takotsubo cardiomyopathy, Kawasaki-like disease and multisystem inflammatory syndrome in children. Imaging can support the management, assessment and prognostic evaluation of these patients. Ultrasound is the most reliable and easy to use in emergency setting and in the ICU as a first approach. The focused approach is useful in management of these patients due its ability to obtain quick and focused results. This tool is useful to evaluate cardiovascular disease and its interplay with lungs. However, a detailed echocardiography evaluation is necessary in a complete assessment of cardiovascular involvement. Computerized tomography is highly sensitive, but it might not always be available. Cardiovascular magnetic resonance and nuclear imaging may be helpful to evaluate COVID-19-related myocardial injury, but further studies are needed. This review deals with different modalities of imaging evaluation in the management of cardiovascular non-ischaemic manifestations of COVID-19, comparing their use in emergency and in intensive care.

Sign in / Sign up

Export Citation Format

Share Document